Looking for a partner interested in the development and
commercialization of a new hypersulphated mini-heparin,
as a potential new antithrombotic agent with clinical
advantages on the available heparins, low molecular
heparins. The product is protected by international
patents. Clinical phase 1 and acute toxicological studies have
been made with success.
Contact: Pier Carlo Montecucchi / Angela Sabella at MonteGen
<www.montegen.com> - Email: innovations at montegen.com; phone:
212-208-2647; fax: 212-208-2648
--
